Linsitinib for active moderate to severe thyroid eye disease
Part of Eyes & vision, Genetic & congenital, Hormones & metabolism, Immune system & allergy clinical trials.
This study tests an experimental pill (linsitinib) for people with active thyroid eye disease. Participation may help reduce eye bulging and other symptoms, especially if other treatments haven't worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have active moderate to severe thyroid eye disease (with symptoms like bulging eyes, eyelid retraction, or double vision) linked to Graves' disease or Hashimoto's thyroiditis.
- Your thyroid eye disease must have been diagnosed within the last 15 months.
- Your thyroid levels should be stable (or only mildly abnormal) based on blood tests.
- You cannot have had orbital surgery, radiation to the eye area, or high-dose steroids for the eye problem within the recent past.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two doses of an oral medication (linsitinib) for people with active, moderate-to-severe thyroid eye disease who were in a previous study and didn't improve enough or had their bulging come back. It aims to see if continuing treatment can help with eye bulging and other symptoms.
This study tests a new medication called GenSci098 for people with active thyroid eye disease. It aims to reduce eye symptoms like redness, swelling, and bulging, and improve quality of life.
This trial tests a new drug called MHB018A for chronic thyroid eye disease (TED)—a condition where the eyes become inflamed and swollen due to thyroid problems. The study aims to see if this treatment can reduce eye inflammation and improve symptoms in people who have had TED for over a year.
This trial tests a new drug called ZL-1109 for people with active, moderate to severe thyroid eye disease (TED). It aims to see if the drug can reduce symptoms like bulging eyes and help patients feel better without using steroids.
This study tests whether tofacitinib, a new type of immune-modulating medication, can help people with moderate-to-severe thyroid eye disease (Graves' orbitopathy) whose eyes haven't improved with standard steroid treatments. The goal is to reduce eye swelling, bulging, and inflammation that affects daily life.
This study tests whether a new medicine called MHB018A can reduce swelling and inflammation in thyroid eye disease (TED)—a condition where the immune system attacks tissues around the eyes, causing them to swell, bulge, and become uncomfortable. Researchers will compare MHB018A to placebo (a fake medicine) to see if it helps improve symptoms and appearance.
Hear when a new Thyroid Eye Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.